(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual revenue growth rate of -26.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Orchestra Biomed Holdings's revenue in 2026 is $33,482,000.On average, 10 Wall Street analysts forecast OBIO's revenue for 2026 to be $185,686,819, with the lowest OBIO revenue forecast at $32,747,126, and the highest OBIO revenue forecast at $282,655,952. On average, 7 Wall Street analysts forecast OBIO's revenue for 2027 to be $195,342,768, with the lowest OBIO revenue forecast at $79,705,467, and the highest OBIO revenue forecast at $313,379,425.
In 2028, OBIO is forecast to generate $964,014,802 in revenue, with the lowest revenue forecast at $315,427,656 and the highest revenue forecast at $2,270,493,917.